



OPEN ACCESS

EDITED AND REVIEWED BY
Michael Heinrich,
University College London, United Kingdom

*CORRESPONDENCE
Guibo Sun,
✉ sunguibo@126.com
Xiaobo Sun,
✉ sun_xiaobo163@163.com

†These authors have contributed equally to
this work

RECEIVED 31 August 2024
ACCEPTED 23 September 2024
PUBLISHED 08 October 2024

CITATION

Deng X, Xing X, Sun G, Xu X, Wu H, Li G and Sun X
(2024) Corrigendum: Guanxin Danshen
formulation protects against myocardial
ischemia reperfusion injury-induced left
ventricular remodeling by upregulating
estrogen receptor β .
Front. Pharmacol. 15:1488968.
doi: 10.3389/fphar.2024.1488968

COPYRIGHT

© 2024 Deng, Xing, Sun, Xu, Wu, Li and Sun. This
is an open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](#). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with these
terms.

Corrigendum: Guanxin Danshen formulation protects against myocardial ischemia reperfusion injury-induced left ventricular remodeling by upregulating estrogen receptor β

Xuehong Deng^{1,2,3,4,5†}, Xiaoyan Xing^{1,2,3,4,5†}, Guibo Sun^{1,2,3,4,5*},
Xudong Xu¹, Haifeng Wu¹, Guang Li^{1,2,3,4,5,6} and Xiaobo Sun^{1,2,3,4,5*}

¹Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Beijing, China, ³Key Laboratory of Efficacy Evaluation of Chinese Medicine against Glycerolipid Metabolism Disorder Disease, State Administration of Traditional Chinese Medicine, Beijing, China, ⁴Zhongguancun Open Laboratory of the Research and Development of Natural Medicine and Health Products, Beijing, China, ⁵Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, China, ⁶Yunnan Branch, Institute of Medicinal Plant, Chinese Academy of Medical Sciences and Peking Union Medical College, Jinghong, China

KEYWORDS

Guanxin Danshen formula, myocardial ischemia reperfusion injury, ventricular remodeling, network pharmacology, estrogen receptor β , PI3K/Akt

A Corrigendum on Guanxin Danshen formulation protects against myocardial ischemia reperfusion injury-induced left ventricular remodeling by upregulating estrogen receptor β

by Deng X, Xing X, Sun G, Xu X, Wu H, Li G and Sun X (2017). *Front. Pharmacol.* 8:777. doi: 10.3389/fphar.2017.00777

In the published article, there was an error in [Figure 4](#) as published. In [Figure 4A](#), the “Sham” and “High dose” group inadvertently used the same representative images as those in [Figure 3A](#). The corrected [Figure 4](#) appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.




FIGURE 4 Echocardiogram parameters in MIRI-LVR rats treated with high-dose of GXDSF treated group and PHTPP. The echocardiograms (A) were obtained using the Vevo 770 high-resolution imaging system. LVEF and LVFS (B) data are also shown in bar graphs. Compared with the sham group, ### $P < 0.001$. Compared with the MIRI-LVR model group: * $P < 0.01$. Compared with the high-dose of GXDSF treated group: & $P < 0.05$, && $P < 0.01$. The data are presented as the mean \pm SD (n = 10 in each group).